These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22001752)

  • 21. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
    Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
    Hübel K; Fresen MM; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; Koristek Z; Kröger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Bone Marrow Transplant; 2012 Aug; 47(8):1046-50. PubMed ID: 22080971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
    Horwitz ME; Long G; Holman P; Libby E; Calandra GC; Schriber JR
    Bone Marrow Transplant; 2012 Oct; 47(10):1283-6. PubMed ID: 22343676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
    Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T
    Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
    Kumar SK; Mikhael J; Laplant B; Lacy MQ; Buadi FK; Dingli D; Gertz MA; Laumann K; Miceli T; Mahlman M; Bergsagel LP; Hayman SR; Reeder C; Stewart AK; Dispenzieri A; Gastineau DA; Winters JL
    Bone Marrow Transplant; 2014 Feb; 49(2):201-5. PubMed ID: 24185588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.
    Johnsrud A; Ladha A; Muffly L; Shiraz P; Goldstein G; Osgood V; Shizuru JA; Johnston L; Arai S; Weng WK; Lowsky R; Rezvani AR; Meyer EH; Frank MJ; Negrin RS; Miklos DB; Sidana S
    Transplant Cell Ther; 2021 Jul; 27(7):590.e1-590.e8. PubMed ID: 33915323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
    Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
    Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers.
    Bilgin YM; Gahar RR; Visser O; Croockewit A; de Greef GE
    Transfus Apher Sci; 2013 Apr; 48(2):191. PubMed ID: 23809830
    [No Abstract]   [Full Text] [Related]  

  • 38. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
    Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
    Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
    Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.